Immunotherapy
News and reporting on cancer immunotherapy.
The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.
Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment
Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.
The company recently published data demonstrating its platform's potential use for prediction and monitoring of immunotherapy response for patients with lung cancer.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
Following a recent leadership change, glycoproteomics firm InterVenn Biosciences is reevaluating its commercial strategy and direction.